Clinical Pearls

The Evolving Field of Treatment Modalities

Morganna Freeman, DO, FACP
Dr Morganna Freeman considers the future application of treatment modalities and how they might be combined for optimal results.

Navigator's Role in Adverse Event Management

Morganna Freeman, DO, FACP
Dr Morganna Freeman recommends that navigators develop a good triage system to effectively manage adverse events.

Is Immunotherapy Appropriate Here?

Morganna Freeman, DO, FACP
Dr Morganna Freeman on the challenge of deciding when to treat a patient with immunotherapy.

Changing the Conversation: Immunotherapy and Long-Term Survival

Morganna Freeman, DO, FACP
Dr Morganna Freeman discusses some of the ways immunotherapy has changed cancer care, including the expectation for long-term survival and how to treat patients in remission.

Choosing Immunotherapy

Morganna Freeman, DO, FACP
Dr Morganna Freeman outlines some of the criteria used in deciding which patients will most benefit from immunotherapy.

Educating Oncology Professionals on Genetic and Genomic Testing

Andrey Antov, PhD, MBA
Dr Andrey Antov provides an overview of the role of Jackson Laboratory in the field of cancer genetic testing and in the education of nurses and navigators who co-manage patients at high risk or with a diagnosis of cancer.

The Future of Genomics and Targeted Therapies

Andrey Antov, PhD, MBA
Dr Andrey Antov muses on the evolution of genomics and how it could potentially impact targeted therapies and cancer care.

Who Should Consider Genetic Testing?

Andrey Antov, PhD, MBA
Dr Andrey Antov identifies situations in which people may want to consider genetic testing.

Genetic vs Genomic Testing: What's the Difference?

Andrey Antov, PhD, MBA
Dr Andrey Antov provides a useful metaphor to explain how genetic testing and genomic testing differ from one another and the purpose behind each type of testing.

Misconceptions About Genetic and Genomic Testing

Andrey Antov, PhD, MBA
Dr Andrey Antov notes that there is often confusion around genetic and genomic testing, due in part to a lack of genetic counselors, high costs, and the rate of adoption of new technologies.